Featured Publications
Profiling cancer testis antigens in non–small-cell lung cancer
Djureinovic D, Hallström B, Horie M, Mattsson J, La Fleur L, Fagerberg L, Brunnström H, Lindskog C, Madjar K, Rahnenführer J, Ekman S, Ståhle E, Koyi H, Brandén E, Edlund K, Hengstler J, Lambe M, Saito A, Botling J, Pontén F, Uhlén M, Micke P. Profiling cancer testis antigens in non–small-cell lung cancer. JCI Insight 2016, 1: e86837. PMID: 27699219, PMCID: PMC5033889, DOI: 10.1172/jci.insight.86837.Peer-Reviewed Original ResearchConceptsCell lung cancerLung cancerCancer testisCTA expressionDifferent normal organsProtein expressionCancer Genome AtlasImmunotherapeutic strategiesPrognostic impactNSCLC casesNSCLC tissuesSurvival associationsNew CTANormal organsBiomarker studiesClinical interestCancerGenome AtlasReliable CTACTANSCLCConcurrent expressionRNAseq dataValuable targetStringent criteria
2024
GP100 expression is variable in intensity in melanoma
Mann J, Hasson N, Su D, Adeniran A, Smalley K, Djureinovic D, Jilaveanu L, Schoenfeld D, Kluger H. GP100 expression is variable in intensity in melanoma. Cancer Immunology, Immunotherapy 2024, 73: 191. PMID: 39105816, PMCID: PMC11303354, DOI: 10.1007/s00262-024-03776-5.Peer-Reviewed Original ResearchMeSH KeywordsAgedBiomarkers, TumorFemaleGp100 Melanoma AntigenHumansImmunohistochemistryMaleMelanomaMiddle AgedSkin NeoplasmsConceptsGp100 expressionCutaneous melanomaTreatment of cutaneous melanomaAdvanced cutaneous melanomaT-cell engagersImprove patient selectionMetastatic melanomaUveal melanomaMetastatic samplesPatient selectionClinical trialsMelanomaQuantitative immunofluorescence methodGp100Improve outcomesImmunofluorescence methodTherapeutic intentDrugCellular productsExpressionTebentafuspImmunohistochemistry
2019
Prognostic Impact of Tumor Cell Programmed Death Ligand 1 Expression and Immune Cell Infiltration in NSCLC
Edlund K, Madjar K, Mattsson J, Djureinovic D, Lindskog C, Brunnström H, Koyi H, Brandén E, Jirström K, Pontén F, Rahnenführer J, Micke P, Hengstler J. Prognostic Impact of Tumor Cell Programmed Death Ligand 1 Expression and Immune Cell Infiltration in NSCLC. Journal Of Thoracic Oncology 2019, 14: 628-640. PMID: 30639618, DOI: 10.1016/j.jtho.2018.12.022.Peer-Reviewed Original ResearchConceptsPD-L1 positivityOverall survivalLymphocyte infiltrationSmoking historyPD-L1Prognostic associationPlasma cellsProgrammed Death Ligand 1 ExpressionTumor PD-L1 positivityDeath ligand 1 (PD-L1) expressionAssociation of lymphocytePositive immune cellsLigand 1 expressionPD-L1 axisPD-L1 statusMultivariate Cox regressionDeath ligand 1Longer overall survivalForkhead box P3Immune cell infiltrationShorter overall survivalPatients' smoking historyKaplan-Meier plotsCheckpoint inhibitorsNSCLC patients
2017
PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability
Brunnström H, Johansson A, Westbom-Fremer S, Backman M, Djureinovic D, Patthey A, Isaksson-Mettävainio M, Gulyas M, Micke P. PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability. Modern Pathology 2017, 30: 1411-1421. PMID: 28664936, DOI: 10.1038/modpathol.2017.59.Peer-Reviewed Original ResearchConceptsPositive tumor cellsTumor cellsLung cancerPD-L1 checkpoint inhibitorsPD-L1 assaysPD-L1 immunohistochemistryCell death 1Squamous cell carcinomaPD-L1 scoresLung cancer casesCheckpoint inhibitorsDeath-1Cell carcinomaClinical studiesCancer casesImmunohistochemical stainingTissue microarrayInterrater variationAntibody 22C3Cutoff levelInter-pathologist variabilityTumor tissueClinical settingSP142Antibody clonesReaching the limits of prognostication in non-small cell lung cancer: an optimized biomarker panel fails to outperform clinical parameters
Grinberg M, Djureinovic D, Brunnström H, Mattsson J, Edlund K, Hengstler J, La Fleur L, Ekman S, Koyi H, Branden E, Ståhle E, Jirström K, Tracy D, Pontén F, Botling J, Rahnenführer J, Micke P. Reaching the limits of prognostication in non-small cell lung cancer: an optimized biomarker panel fails to outperform clinical parameters. Modern Pathology 2017, 30: 964-977. PMID: 28281552, DOI: 10.1038/modpathol.2017.14.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorCarcinoma, Non-Small-Cell LungCell Adhesion Molecule-1Enhancer of Zeste Homolog 2 ProteinGlucose Transporter Type 1HumansImmunohistochemistryIntracellular Signaling Peptides and ProteinsLung NeoplasmsNuclear ProteinsPrognosisThyroid Nuclear Factor 1Tissue Array AnalysisConceptsNon-small cell lung cancerCell lung cancerNon-small cell lung cancer patientsCell lung cancer patientsLung cancer patientsLung cancerBiomarker panelClinical parametersCancer patientsPrognostic associationClinicopathological parametersClinical practicePrognostic modelSurvival predictionProtein expressionBest prognostic modelPrognostic biomarker panelBetter prognostic performanceImmunohistochemistry-based assessmentCorresponding concordance indexProtein biomarkersClinicopathological dataConcordance indexPrognostic performanceTissue microarray
2016
The Human Adrenal Gland Proteome Defined by Transcriptomics and Antibody-Based Profiling
Bergman J, Botling J, Fagerberg L, Hallström B, Djureinovic D, Uhlén M, Pontén F. The Human Adrenal Gland Proteome Defined by Transcriptomics and Antibody-Based Profiling. Endocrinology 2016, 158: 239-251. PMID: 27901589, DOI: 10.1210/en.2016-1758.Peer-Reviewed Original ResearchConceptsImmunohistochemistry-based protein profilingNormal human tissue typesProtein coding genesMessenger RNA sequencingExpression levelsProtein expression patternsHuman tissue typesCoding genesProtein homologsFERM domainRelative expression levelsCorresponding proteinRNA sequencingWide transcriptomicsExpression patternsProtein profilingGreater expression levelsGenesSpecific functionsProteinMolecular landscapeTissue typesProteomeTranscriptomicsElevated expressionThe Impact of the Fourth Edition of the WHO Classification of Lung Tumours on Histological Classification of Resected Pulmonary NSCCs
Micke P, Mattsson J, Djureinovic D, Nodin B, Jirström K, Tran L, Jönsson P, Planck M, Botling J, Brunnström H. The Impact of the Fourth Edition of the WHO Classification of Lung Tumours on Histological Classification of Resected Pulmonary NSCCs. Journal Of Thoracic Oncology 2016, 11: 862-872. PMID: 26872818, DOI: 10.1016/j.jtho.2016.01.020.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, Large CellCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellFemaleHumansImmunohistochemistryLung NeoplasmsMaleMiddle AgedNeoplasm StagingNeuroendocrine TumorsPrognosisSmall Cell Lung CarcinomaWorld Health OrganizationConceptsNon-small cell carcinomaPulmonary non-small cell carcinomaCell carcinomaWHO classificationLung tumorsFourth EditionWorld Health Organization classificationLarge cell carcinomaSquamous cell carcinomaThyroid transcription factor-1Cases of adenocarcinomaMost patientsHistological typeAdenocarcinoma groupAdenocarcinomatous differentiationOrganization classificationLung cancerNeuroendocrine tumorsTranscription factor 1Napsin AHistological classificationIHC markersHistopathological classificationImmunohistochemical stainingIHC staining
2014
The human testis-specific proteome defined by transcriptomics and antibody-based profiling
Djureinovic D, Fagerberg L, Hallström B, Danielsson A, Lindskog C, Uhlén M, Pontén F. The human testis-specific proteome defined by transcriptomics and antibody-based profiling. Molecular Human Reproduction 2014, 20: 476-488. PMID: 24598113, DOI: 10.1093/molehr/gau018.Peer-Reviewed Original ResearchConceptsExpression patternsAntibody-based protein profilingTestis-enriched expression patternNormal human tissue typesWide transcriptomic analysisTissue-specific genesAntibody-based profilingPutative human genesList of genesHaploid germ cellsHuman tissue typesDifferent cell typesHuman reproductive biologyReproductive biologyWide analysisProtein localizationHuman genesTranscriptomic analysisCorresponding proteinStages of spermatogenesisDeep sequencingProtein profilingMolecular understandingGerm cellsGenes
2013
A systematic analysis of commonly used antibodies in cancer diagnostics
Gremel G, Bergman J, Djureinovic D, Edqvist P, Maindad V, Bharambe B, Khan W, Navani S, Elebro J, Jirström K, Hellberg D, Uhlén M, Micke P, Pontén F. A systematic analysis of commonly used antibodies in cancer diagnostics. Histopathology 2013, 64: 293-305. PMID: 24330150, DOI: 10.1111/his.12255.Peer-Reviewed Original ResearchMeSH KeywordsAntibodiesBiomarkers, TumorHumansImmunohistochemistryNeoplasmsSensitivity and SpecificityConceptsDifferential diagnosticsCancer typesBenefit of immunohistochemistryTissue microarray cohortProstate-specific antigenEvidence-based dataCombination of antibodiesNumber of antibodiesMicroarray cohortMetastatic lesionsPrimary tumorClinical ImmunohistochemistryNovel markerImmunohistochemistryTumor samplesAntibodiesTumorsDiagnostic powerConsecutive sectionsDiagnostic antibodiesDifferent organsPresent studyPivotal roleCancer diagnosticsOptimal use